HeXun Biosciences Co (ROCO:6986) Other Stockholders Equity: NT$-0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6986 HeXun Biosciences Co Ltd ROCO:6986
22 GF Score
Price NT$43.70
! 2 Warning Signs
View Full Analysis

What is HeXun Biosciences Co Other Stockholders Equity?

HeXun Biosciences Co ROCO:6986 22 Other Stockholders Equity is NT$-0.0 Mil as of Mar. 2026. GuruFocus rates ROCO:6986 with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

HeXun Biosciences Co's Other Stockholders Equity for the quarter that ended in Mar. 2026 was NT$-0.0 Mil.

HeXun Biosciences Co's quarterly Other Stockholders Equity stayed the same from Sep. 2025 (NT$0.0 Mil) to Dec. 2025 (NT$0.0 Mil) but then declined from Dec. 2025 (NT$0.0 Mil) to Mar. 2026 (NT$-0.0 Mil).

HeXun Biosciences Co's annual Other Stockholders Equity declined from Dec. 2023 (NT$0.0 Mil) to Dec. 2024 (NT$0.0 Mil) but then stayed the same from Dec. 2024 (NT$0.0 Mil) to Dec. 2025 (NT$0.0 Mil).

HeXun Biosciences Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for HeXun Biosciences Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeXun Biosciences Co Other Stockholders Equity Chart

HeXun Biosciences Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

HeXun Biosciences Co Quarterly Data
Dec20 Dec21 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.00
ROCO:6986
22GF Score
HeXun Biosciences Co Ltd ROCO:6986
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HeXun Biosciences Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of NT$-0.0 Mil mean?
HeXun Biosciences Co (ROCO:6986) has a Other Stockholders Equity of NT$-0.0 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on HeXun Biosciences Co and its competitors.
Is HeXun Biosciences Co's Other Stockholders Equity too high?
HeXun Biosciences Co's current Other Stockholders Equity is NT$-0.0 Mil. Overall, HeXun Biosciences Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does HeXun Biosciences Co's Other Stockholders Equity compare to VRTX and REGN?
HeXun Biosciences Co's Other Stockholders Equity of NT$-0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on HeXun Biosciences Co and its competitors. HeXun Biosciences Co's current Other Stockholders Equity is NT$-0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeXun Biosciences Co stock overvalued right now?
HeXun Biosciences Co (ROCO:6986) has a current Other Stockholders Equity of NT$-0.0 Mil. The current Other Stockholders Equity is NT$-0.0 Mil. HeXun Biosciences Co's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For HeXun Biosciences Co (ROCO:6986), the current Other Stockholders Equity is NT$-0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HeXun Biosciences Co Business Description

Address Chunri Road, 6 F., No. 1490, Taoyuan District, Taoyuan, TWN
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
22GF Score

Get the complete analysis for ROCO:6986

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$43.70
Price